Background <p>Tumor-associated macrophages (TAMs) are key drivers of the immunosuppressive tumor microenvironment (TME), thereby limiting the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear.</p> Methods <p>Both genetic (Akr1b3 knockout) and pharmacologic (epalrestat) approaches were employed to examine the impact of Aldo-keto reductase family 1 member B1 (AKR1B1) inhibition on TAMs and T-cell function in vitro and…
Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity
Journal for ImmunoTherapy of Cancer | | Liu, Y., Zhou, C., Tang, Y., Lei, H., Aihemaiti, A., Liu, H., Zou, P., Xie, J., Guo, X., Xia, R., Han, B.-H., Chen, H., Zhu, L.
Topics: immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer